



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/669,861

09/24/2003

Dong-Ki Lee

12279-007002

4394

26161 7590 05/16/2007
FISH & RICHARDSON PC
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER

DUNSTON, JENNIFER ANN

ART UNIT

PAPER NUMBER

1636

MAIL DATE

DELIVERY MODE

05/16/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/669,861

Applicant(s)

LEE ET AL.

Examiner

Jennifer Dunston

Art Unit

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 April 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 2,3,5,6,13-19 and 22-41 is/are pending in the application.
- 4a) Of the above claim(s) 13,15-19,28,29 and 32-35 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 2,3,5,6,14,22-27,30,31 and 36-41 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 24 June 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>11/26/2004, 12/22/2005</u> . | 6) <input checked="" type="checkbox"/> Other: <u>Exhibits I-IV</u> . |

DETAILED ACTION

Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.

Any rejection of record in the previous office actions not addressed herein is withdrawn. New grounds of rejection are presented herein that were not necessitated by applicant's amendment of the claims since the final Office action mailed 1/9/2007.

Receipt is acknowledged of an amendment, filed 4/9/2007, in which claims 1, 4, 7-12 and 20-21 were canceled, claims 13-14 and 30-31 were amended. Currently, claims 2-3, 5-6, 13-19 and 22-41 are pending.

Election/Restrictions

Applicant elected Group I without traverse in the reply filed on 12/22/2005.

Claims 13, 15-19, 28-29 and 32-35 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 12/22/2005. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. In the instant case, all product claims are not found allowable.

Currently, claims 2-3, 5-6, 14, 22-27, 30-31 and 36-41 are under consideration.

Priority

Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119 as follows:

The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994).

The disclosure of the prior-filed application, Application No. 60/338,441, fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application. The prior-filed provisional application does not provide teach how to make and use an isolated transcription factor that comprises at least one zinc finger domain, wherein the presence of the transcription factor in a cell can alter the differentiation state of the cell. The provisional application does not describe proteins that comprise at least one zinc finger domain and can alter the differentiation state of a cell. The specification of the provisional application does not describe zinc fingers that can induce a neuronal phenotype in a vertebrate cells such as a neuroblastoma cell. The specification of the provisional application does not describe a protein comprising a first, second and third zinc finger domains, wherein the contacting residues of the first, second, and third domains at

Art Unit: 1636

positions -1, 2, 3, and 6 of each domain respectively correspond to the motifs: QSNR, ZSNK, and CSNR, such as the zinc finger array of SEQ ID NO: 2.

Claims 1-6, 14, 22-27 and 30-31 have an effective filing date of 4/26/2002.

Sequence Compliance

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below.

Figure 10B contains a nucleic acid sequence that is not referred to by the use of a sequence identifier. Where the description or claims of a patent application discuss a sequence that is set forth in the Sequence Listing, reference must be made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO: " in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application.

In response to this office action, Applicant must comply with the sequence rules, 37 CFR 1.821 - 1.825. It would be remedial to amend the brief description of Figure 10B to refer to the nucleic acid sequence as SEQ ID NO: 130. The nature of the non-compliance did not preclude an examination of the elected invention on the merits, the results of which are presented below.

Art Unit: 1636

Specification

The abstract of the disclosure is objected to because the phrase “at least one zinc finger domains” is not grammatically correct. It would be remedial to amend the phrase to “at least one zinc finger domain.” Correction is required. See MPEP § 608.01(b).

Response to Arguments - 35 USC § 101

The rejection of claims 14, 30 and 31 under 35 U.S.C. 101 has been withdrawn in view of Applicant’s amendment to the claims in the reply filed 4/9/2007. The amendment limits the cells to isolated cells.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 2-3, 5, 22-27, 30-31 and 36-38 are rejected under 35 U.S.C. 102(e) as being anticipated by Kim et al (US Patent Application Publication NO. 2003/0165997 A1, cited on the IDS filed 11/26/2004; see the entire reference).

The applied reference has a common inventor and assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing

Art Unit: 1636

under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Regarding claim 5, Kim et al teach a zinc finger polypeptide comprising a first, second, and third zinc finger domain, where each zinc finger domain is selected from the zinc fingers in Tables 5, 6 and 7. Kim et al teach the zinc fingers of QSNR and CSNK in Table 5, and the zinc finger of QSNK in Table 6.

Regarding claims 2, 3 and 24, the zinc finger of Kim et al meets the structural limitations of claim 5, and thus it would necessarily be capable of altering the differentiation state of the cell where the cells is a vertebrate cell or a mouse neuroblastoma cell. The presence of the transcription factor in the cell would be capable of inducing a neural phenotype or neurite extension. Further, Kim et al teach that the zinc fingers of QSNR, CSNK and QSNK each bind preferentially to the GAA sequence (e.g., Tables 5 and 6) and thus would be capable of regulating sequences operatively linked to the GAA elements.

Regarding claims 22 and 23, Kim et al teach that the zinc finger domains of Tables 5, 6 and 7 are from different naturally human occurring proteins (e.g., paragraphs [0025]-[0026] and [0118]; Table X).

Regarding claims 25-27, Kim et al teach the polypeptide further comprising an activation domain (e.g., paragraph [0028]).

Regarding claims 30-31, Kim et al teach a cell comprising the polypeptide (e.g., paragraph [0105]).

Art Unit: 1636

Regarding claims 36-38, Kim et al teach the following amino acid sequences for each of the QSNR, QSNK, and CSNK zinc fingers respectively: SEQ ID NO: 47, SEQ ID NO: 179 and SEQ ID NO: 23 (e.g., paragraphs [0104], [0314], [0350] and [0458]). SEQ ID NO: 47 of Kim et al is 100% identical to instant SEQ ID NO: 47. SEQ ID NO: 179 of Kim et al is 100% identical to instant SEQ ID NO: 162. SEQ ID NO: 23 of Kim et al is 100% identical to instant SEQ ID NO: 173. See the attached alignments in Exhibits I-III.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 6, 14 and 39-41 are rejected under 35 U.S.C. 103(a) as being obvious over Kim et al (US Patent Application Publication NO. 2003/0165997 A1, cited on the IDS filed 11/26/2004;

Art Unit: 1636

see the entire reference) in view of Liu et al (PNAS, Vol. 94, pages 5525-5530, May 1997; see the entire reference).

The applied reference has a common inventor and assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art only under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention "by another"; (2) a showing of a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). This rejection might also be overcome by showing that the reference is disqualified under 35 U.S.C. 103(c) as prior art in a rejection under 35 U.S.C. 103(a). See MPEP § 706.02(l)(1) and § 706.02(l)(2).

Kim et al teach a zinc finger polypeptide comprising a first, second, and third zinc finger domain, where each zinc finger domain is selected from the zinc fingers in Tables 5, 6 and 7. Kim et al teach the zinc fingers of QSNR and CSNK in Table 5, and the zinc finger of QSNK in Table 6. The zinc finger of Kim et al meets the structural limitations of claim 5, and thus it would necessarily be capable of altering the differentiation state of the cell where the cells is a vertebrate cell or a mouse neuroblastoma cell. The presence of the transcription factor in the cell would be capable of inducing a neural phenotype or neurite extension. Further, Kim et al teach

Art Unit: 1636

that the zinc fingers of QSNR, CSNK and QSNK each bind preferentially to the GAA sequence (e.g., Tables 5 and 6) and thus would be capable of regulating any sequences operatively linked to a regulatory region comprising the GAA sequence elements. Kim et al teach the following amino acid sequences for each of the QSNR, QSNK, and CSNK zinc fingers respectively: SEQ ID NO: 47, SEQ ID NO: 179 and SEQ ID NO: 23 (e.g., paragraphs [0104], [0314], [0350] and [0458]). SEQ ID NO: 47 of Kim et al is 100% identical to instant SEQ ID NO: 47. SEQ ID NO: 179 of Kim et al is 100% identical to instant SEQ ID NO: 162. SEQ ID NO: 23 of Kim et al is 100% identical to instant SEQ ID NO: 173. See the attached alignments in Exhibits I-III.

Further, Kim et al teach that the zinc finger domains are positioned adjacent to each other to form an array of zinc finger domains, which is a polypeptide unit that is uninterrupted by other types of structural or functional protein domains (e.g., paragraph [0025]).

Kim et al do not teach a polypeptide that comprises amino acids 31-109 of instant SEQ ID NO: 2.

Liu et al teach the design of a linker peptide, TGEKP, to link zinc finger domains of synthetic zinc finger transcription factors (e.g., pages 5527-5528, Design of a Linker Peptide). Liu et al teach that the linker should be of general utility in the construction of zinc finger proteins with genome-specific addressing potential (e.g., page 5529, right column, 1st paragraph).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to polypeptide of Kim et al to specifically include the TGEKP linker sequence between zinc fingers 1 and 2 and zinc fingers 2 and 3 taught by Kim et al because Kim et al teach it is within the ordinary skill in the art to use an array of zinc finger proteins without any

Art Unit: 1636

intervening domains and Liu et al teach the TGEKP linker sequence in order to link zinc finger domains for binding of DNA.

One would have been motivated to make such a modification in order to receive the expected benefit of designing a zinc finger polypeptide with the zinc fingers properly spaced such that they could bind a GAAGAAGAA DNA sequence as taught by Kim et al (Tables 5 and 6; Figure 2). Based upon the teachings of the cited references, the high skill of one of ordinary skill in the art, and absent any evidence to the contrary, there would have been a reasonable expectation of success to result in a polypeptide of amino acids 31-109 of SEQ ID NO: 2. See the attached alignment in Exhibit IV, which compares the sequences of Kim et al (SEQ ID NOS: 47, 179 and 23, respectively) linked with the TGEKP linker of Liu et al to amino acids 31 to 109 of instant SEQ ID NO: 2.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Dunston whose telephone number is 571-272-2916. The examiner can normally be reached on M-F, 9 am to 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached at 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1636


Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jennifer Dunston, Ph.D.

Examiner

Art Unit 1636

jad



CELINE QIAN, PH.D.
PRIMARY EXAMINER

Exhibit I : Instant SEQ ID NO: 177

```
<!--StartFragment-->RESULT 2
US-10-223-765-47
; Sequence 47, Application US/10223765
; Publication No. US20030165997A1
; GENERAL INFORMATION:
; APPLICANT: Kim, Jin-Soo
; APPLICANT: Bae, Kwang-Hee
; APPLICANT: Park, Kyung-Soon
; APPLICANT: Kwon, Young Do
; APPLICANT: Ryu, Eun-Hyun
; APPLICANT: Hwang, Moon-Sun
; TITLE OF INVENTION: ZINC FINGER DOMAIN LIBRARIES
; FILE REFERENCE: 12279-005001
; CURRENT APPLICATION NUMBER: US/10/223,765
; CURRENT FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: 60/374,355
; PRIOR FILING DATE: 2002-04-22
; PRIOR APPLICATION NUMBER: 60/313,402
; PRIOR FILING DATE: 2001-08-17
; NUMBER OF SEQ ID NOS: 305
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 47
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-223-765-47
```

```
Query Match          100.0%; Score 129; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 7e-12;
Matches    23; Conservative    0; Mismatches    0; Indels    0; Gaps    0;
```

```
Qy      1 FECKDCGKAFIQKSNLIRHQRT 23
        |||
Db      1 FECKDCGKAFIQKSNLIRHQRT 23
<!--EndFragment-->
```

Exhibit II : Instant SEQ ID NO: 162

```

<!--StartFragment-->RESULT 1
US-10-223-765-179
; Sequence 179, Application US/10223765
; Publication No. US20030165997A1
; GENERAL INFORMATION:
; APPLICANT: Kim, Jin-Soo
; APPLICANT: Bae, Kwang-Hee
; APPLICANT: Park, Kyung-Soon
; APPLICANT: Kwon, Young Do
; APPLICANT: Ryu, Eun-Hyun
; APPLICANT: Hwang, Moon-Sun
; TITLE OF INVENTION: ZINC FINGER DOMAIN LIBRARIES
; FILE REFERENCE: 12279-005001
; CURRENT APPLICATION NUMBER: US/10/223,765
; CURRENT FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: 60/374,355
; PRIOR FILING DATE: 2002-04-22
; PRIOR APPLICATION NUMBER: 60/313,402
; PRIOR FILING DATE: 2001-08-17
; NUMBER OF SEQ ID NOS: 305
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 179
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-223-765-179

```

```

Query Match          100.0%;  Score 129;  DB 4;  Length 23;
Best Local Similarity 100.0%;  Pred. No. 2.4e-11;
Matches 23;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

```

```

Qy      1 YKCEECGKAFTQSSNLTKHKKIH 23
        |||
Db      1 YKCEECGKAFTQSSNLTKHKKIH 23
<!--EndFragment-->

```

Exhibit III

Instant SEQ ID NO: 173

```

<!--StartFragment-->RESULT 1
US-10-223-765-23
; Sequence 23, Application US/10223765
; Publication No. US20030165997A1
; GENERAL INFORMATION:
; APPLICANT: Kim, Jin-Soo
; APPLICANT: Bae, Kwang-Hee
; APPLICANT: Park, Kyung-Soon
; APPLICANT: Kwon, Young Do
; APPLICANT: Ryu, Eun-Hyun
; APPLICANT: Hwang, Moon-Sun
; TITLE OF INVENTION: ZINC FINGER DOMAIN LIBRARIES
; FILE REFERENCE: 12279-005001
; CURRENT APPLICATION NUMBER: US/10/223,765
; CURRENT FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: 60/374,355
; PRIOR FILING DATE: 2002-04-22
; PRIOR APPLICATION NUMBER: 60/313,402
; PRIOR FILING DATE: 2001-08-17
; NUMBER OF SEQ ID NOS: 305
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-223-765-23

```

```

Query Match          100.0%; Score 139; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.5e-11;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 YKCKQCGKAFGCPSNLRRHGRTH 23
        |||
Db      1 YKCKQCGKAFGCPSNLRRHGRTH 23
<!--EndFragment-->

```

Exhibit IV

**Blast 2 Sequences results**

PubMed

Entrez

BLAST

OMIM

Taxonomy


Structure

BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.16 [Mar-25-2007]

Matrix **BLOSUM62** gap open: **11** gap extension: **1**
x_dropoff: **0** expect: **10.0000** wordsize: **3** Filter ☒ View option **Standard**
Masking character option **X for protein, n for nucleotide** Masking color option **Black**
☐ Show CDS translation **Align**

Sequence 1: lcl|seq_1
Length = 79 (31 .. 109)

Sequence 2: lcl|seq_2
Length = 79 (1 .. 79)



NOTE:Bitscore and expect value are calculated based on the size of the nr database.



Score = 122 bits (306), Expect = 5e-27, Method: Composition-based stats.
Identities = 79/79 (100%), Positives = 79/79 (100%), Gaps = 0/79 (0%)

Query	31	FECKDCGKAFIQKSNLIRHQRTHTGEKPYKCEECGKAFTQSSNLTKHKKIHTGEKPYKCK	90
		FECKDCGKAFIQKSNLIRHQRTHTGEKPYKCEECGKAFTQSSNLTKHKKIHTGEKPYKCK	
Sbjct	1	FECKDCGKAFIQKSNLIRHQRTHTGEKPYKCEECGKAFTQSSNLTKHKKIHTGEKPYKCK	60
Query	91	QCGKAFGCPSNLRRHGRTH	109
		QCGKAFGCPSNLRRHGRTH	
Sbjct	61	QCGKAFGCPSNLRRHGRTH	79

CPU time: 0.03 user secs. 0.01 sys. secs 0.04 total secs.